Brazilian Sepsis Epidemiological Study (BASES study)

Eliézer Silva, Marcelo de Almeida Pedro, Ana Cristina Beltrami Sogayar, Tatiana Mohovic, Carla Lika de Oliveira Silva, Mariano Janiszewski, Ruy Guilherme Rodrigues Cal, Erica Fernandes de Sousa, Thereza Phitoe Abe, Joel de Andrade, Jorge Dias de Matos, Ederlon Rezende, Murillo Assunção, Alvaro Avezum, Patrícia C S Rocha, Gustavo Faissol Janot de Matos, André Moreira Bento, Alice Danielli Corrêa, Paulo Cesar Bastos Vieira, Elias Knobel, Brazilian Sepsis Epidemiological Study, Eliézer Silva, Marcelo de Almeida Pedro, Ana Cristina Beltrami Sogayar, Tatiana Mohovic, Carla Lika de Oliveira Silva, Mariano Janiszewski, Ruy Guilherme Rodrigues Cal, Erica Fernandes de Sousa, Thereza Phitoe Abe, Joel de Andrade, Jorge Dias de Matos, Ederlon Rezende, Murillo Assunção, Alvaro Avezum, Patrícia C S Rocha, Gustavo Faissol Janot de Matos, André Moreira Bento, Alice Danielli Corrêa, Paulo Cesar Bastos Vieira, Elias Knobel, Brazilian Sepsis Epidemiological Study

Abstract

Introduction: Consistent data about the incidence and outcome of sepsis in Latin American intensive care units (ICUs), including Brazil, are lacking. This study was designed to verify the actual incidence density and outcome of sepsis in Brazilian ICUs. We also assessed the association between the Consensus Conference criteria and outcome

Methods: This is a multicenter observational cohort study performed in five private and public, mixed ICUs from two different regions of Brazil. We prospectively followed 1383 adult patients consecutively admitted to those ICUs from May 2001 to January 2002, until their discharge, 28th day of stay, or death. For all patients we collected the following data at ICU admission: age, gender, hospital and ICU admission diagnosis, APACHE II score, and associated underlying diseases. During the following days, we looked for systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock criteria, as well as recording the sequential organ failure assessment score. Infection was diagnosed according to CDC criteria for nosocomial infection, and for community-acquired infection, clinical, radiological and microbiological parameters were used.

Results: For the whole cohort, median age was 65.2 years (49-76), median length of stay was 2 days (1-6), and the overall 28-day mortality rate was 21.8%. Considering 1383 patients, the incidence density rates for sepsis, severe sepsis and septic shock were 61.4, 35.6 and 30.0 per 1000 patient-days, respectively. The mortality rate of patients with SIRS, sepsis, severe sepsis and septic shock increased progressively from 24.3% to 34.7%, 47.3% and 52.2%, respectively. For patients with SIRS without infection the mortality rate was 11.3%. The main source of infection was lung/respiratory tract.

Conclusion: Our preliminary data suggest that sepsis is a major public health problem in Brazilian ICUs, with an incidence density about 57 per 1000 patient-days. Moreover, there was a close association between ACCP/SCCM categories and mortality rate.

Figures

Figure 1
Figure 1
Flow diagram of enrolled patients and their mortality rate according to Consensus Conference categories. ICU, intensive care unit; SIRS, systemic inflammatory response syndrome.
Figure 2
Figure 2
Overall mortality rate and sepsis-related mortality rate according to American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions. A progressively higher mortality was observed as systemic inflammatory response syndrome (SIRS) was due to infection, namely sepsis, and as more severe organ dysfunctions were present, namely severe sepsis and septic shock. The first column shows mortality from the group of patients who met SIRS criteria but who had no infection; in that case there was no sepsis-related death.
Figure 3
Figure 3
Kaplan–Meier survival curve for intensive care unit admissions with sepsis and without sepsis.

References

    1. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138–150. doi: 10.1056/NEJMra021333.
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ., Jr Recombinant human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001.
    1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–1377. doi: 10.1056/NEJMoa010307.
    1. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med. 1998;26:2078–2086. doi: 10.1097/00003246-199812000-00045.
    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–1310. doi: 10.1097/00003246-200107000-00002.
    1. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 2002;28:108–121. doi: 10.1007/s00134-001-1143-z.
    1. Annane D, Aegerter P, Jars-Guincestre MC, Guidetfor B. Current epidemiology of septic shock: The CUB-Réa Network. Am J Respir Crit Care Med. 2003;168:165–172. doi: 10.1164/rccm.2201087.
    1. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, Light B, Spapen H, Stone J, Seibert A, Peckelsen C, De Deyne C, Postier R, Pettila V, Artigas A, Percell SR, Shu V, Zwingelstein C, Tobias J, Poole L, Stolzenbach JC, Creasey AA, (OPTIMIST Trial Study Group) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290:238–247. doi: 10.1001/jama.290.2.238.
    1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874.
    1. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273:117–123. doi: 10.1001/jama.273.2.117.
    1. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–710. doi: 10.1007/s001340050156.
    1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–140.
    1. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Khan KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Scwartz JS, Moore R, Johnson BL, Platt R. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA. 1997;278:234–240. doi: 10.1001/jama.278.3.234.
    1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System. Am J Med. 1991;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3.
    1. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274:968–974. doi: 10.1001/jama.274.12.968.
    1. Salvo I, de Cian W, Musicco M, Langer M, Piadena R, Wolfler A, Montani C, Magni E. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med. 1995;21:S244–S249.
    1. Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. Q J Med. 1996;89:515–522.
    1. Yu DT, Black E, Sands KE, Schwartz JS, Hibberd PL, Graman PS, Lanken PN, Kahn KL, Snydman DR, Parsonnet J, Moore R, Platt R, Bates DW, for the Academic Medical Center Consortium Sepsis Project Working Group Severe sepsis: variation in resource and therapeutic modality use among academic centers. Crit Care. 2003;7:R24–R34. doi: 10.1186/cc2171.
    1. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of infection in intensive care (EPIC) Study. JAMA. 1995;274:639–644. doi: 10.1001/jama.274.8.639.
    1. Ewig S, Torres A. Prevention and management of ventilator-associated pneumonia. Curr Opin Crit Care. 2002;8:58–69. doi: 10.1097/00075198-200202000-00010.
    1. Curtis JR. The long-term outcomes of mechanical ventilation: what are they and how should they be used? Respir Care. 2002;47:496–505.
    1. Knaus WA, Sun X, Nystrom O, Wagner DP. Evaluation of definitions for sepsis. Chest. 1992;101:1656–1662.
    1. Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA. 1997;277:1058–1063. doi: 10.1001/jama.277.13.1058.
    1. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM, for the KyberSept Trial Study Group Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286:1869–1878. doi: 10.1001/jama.286.15.1869.
    1. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862. doi: 10.1001/jama.288.7.862.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel